<DOC>
	<DOCNO>NCT01859390</DOCNO>
	<brief_summary>The purpose study evaluate effect modify formulation AquADEKs ( AquADEKs-2 ) marker inflammation , antioxidant level oxidative stress . Cystic Fibrosis ( CF ) disease affect organs body lung . Some damage lung CF patient may cause something call oxidant/antioxidant imbalance oxidative stress . Oxidation body kind happen apple turn brown cut . And , squeeze lemon juice stop oxidation apple , antioxidant stop rusting ( damage ) inside body unstable oxygen molecule call free radical . Free radical help fight bacteria viruses many damage instead . Our body need antioxidant keep thing balance right amount free radical . Many CF patient also trouble digest food absorb nutrient like vitamin . Many vitamin rely antioxidant , like vitamin A , D , E , K beta-carotene . In people CF , even though take multivitamin pancreatic enzyme , still low amount antioxidant . We look see take vitamin antioxidant help CF patient . AquADEKs-2 investigational new drug ( drug receive approval Food Drug Administration [ FDA ] ) . This research study do AquADEKs-2 compare control multivitamin . The study drug , AquADEKs-2 contain standard amount fat-soluble vitamin ( A , D , E , K ) contain typical CF multivitamin supplement plus several antioxidant include beta-carotene , mixed tocopherol ( different form vitamin E ) , coenzyme Q10 ( CoQ10 ) , mixed carotenoid ( lutein , lycopene zeaxanthin ) , mineral zinc selenium . The control multivitamin contain standard amount vitamins A , B , D , E , K without additional antioxidant supplementation .</brief_summary>
	<brief_title>Effects Antioxidant-Enriched Multivitamin Supplement Inflammation Oxidative Stress Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Male female ≥10 year age Documentation Cystic Fibrosis ( CF ) diagnosis evidence 1 clinical feature consistent CF phenotype 1 follow criterion : Sweat chloride equal great 60 milliequivalent ( mEq/L ) quantitative pilocarpine iontophoresis test ( QPIT ) 2 wellcharacterized mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) gene Pancreatic insufficiency document spot fecal elastase1 ( FE1 ) ≤ 100μg/g stool sample do either historically screen visit Clinically stable significant change health status within 2 week prior randomization FEV1 ≥ 40 ≤ 100 % predict age base Wang ( male &lt; 18 year , females &lt; 16 year ) Hankinson ( male ≥ 18 year , females ≥ 16 year ) standardize equation screen visit Weight ≥ 30 kg screen visit Able perform repeatable , consistent effort pulmonary function test Able tolerate sputum induction 3 % hypertonic saline expectorate induction Written inform consent ( assent applicable ) obtain subject subject 's legal representative Ability swallow softgel capsule Subjects treat ivacaftor ( Kalydeco™ ) Liver enzymes aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gammaglutamyl transferase ( GGT ) &gt; 3 time upper limit normal screen visit Use antibiotic ( oral , iv , and/or inhale ) acute respiratory symptom within 2 week prior randomization Active treatment allergic bronchopulmonary aspergillosis ( ABPA ) Current use oral corticosteroid dos exceed equivalent 10 mg prednisone/day 20 mg prednisone every day Active treatment nontuberculous mycobacterial ( NTM ) infection Initiation new chronic therapy ( e.g. , ibuprofen , Pulmozyme® , hypertonic saline , azithromycin , Tobramycin Inhalation solution ( TOBI® ) , Cayston® within 8 week prior randomization Unwilling discontinue current oral vitamin antioxidant supplementation ( e.g. , AquADEKs® , another source βcarotene , vitamin A , vitamin E tocopherol , vitamin D K , nacetylcysteine , glutathione , CoQ10 , overthecounter antioxidant ) duration study Use vitamin ( control vitamin ) antioxidant within 4 week prior randomization Daily use &gt; 2 can Boost Pulmocare dietary supplement formula Known hypersensitivity oral AquADEKs® For woman child bear potential : 1. positive pregnancy test Visit 1 Visit 2 , 2. lactate 3. unwilling practice medically acceptable form contraception ( acceptable form contraception : abstinence , hormonal birth control , intrauterine device , barrier method plus spermicidal agent ) Subject unlikely complete study determine Investigator Any condition Investigator believe would interfere intent study would make participation best interest subject Use investigational therapy within 4 week prior randomization Current tobacco smoker Current use anticoagulant medication Severe malnutrition base either BMI le 5th percentile subject &lt; 18 year age BMI le 18 kg/m2 subject &gt; 18 year age . Subjects poorly control CFrelated diabetes active insulin therapy , define Glycosylated Hemoglobin ( HgbA1c ) ≥ 7.5 % recent historic evaluation HgbA1c</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Antioxidants</keyword>
	<keyword>Vitamins</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Oxidative stress</keyword>
</DOC>